Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00454857
Other study ID # 20050237
Secondary ID
Status Completed
Phase N/A
First received March 29, 2007
Last updated October 23, 2013
Start date May 2006
Est. completion date August 2008

Study information

Verified date October 2013
Source Amgen
Contact n/a
Is FDA regulated No
Health authority Australia: Department of Health and Ageing Therapeutic Goods AdministrationAustralia: Human Research Ethics CommitteeAustralia: Therapeutic Goods AdministrationCanada: Health CanadaCanada: Health Products and Food BranchEU: CHMPEuropean Union: European Medicines AgencyFrance and Sweden: European Medicines AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)France: Ministry of HealthGermany: Federal Institute for Drugs and Medical DevicesGermany: Paul_Ehrlich-Institut Bundesamt fur Sera und ImpfstoffeItaly: Ministry of HealthSpain: Spanish Agency of MedicinesSpain: Spanish Drug AgencyUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This is a multi-center prospective observational descriptive study complemented by a retrospective chart review. Patients diagnosed with ITP and currently treated for ITP by a hematologist or hematologist-oncologist will be recruited from community-based clinics and academic/referral centers. They will be followed prospectively for a period of 12 months. At inception, participants' charts will also be reviewed from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever is less.


Description:

Time Perspective: 12 months prospective chart review study with a retrospective chart review for a period up to 36 months from the start of the study, since the date of diagnosis for ITP.


Recruitment information / eligibility

Status Completed
Enrollment 326
Est. completion date August 2008
Est. primary completion date June 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Has a diagnosis of ITP according to the American Society of Hematology guidelines (George et al., 1996).

- Is equal to or greater than 18 years of age.

- Is willing and able to complete a series of questionnaires.

- Before any study-specific procedure, the appropriate written informed consent must be obtained.

Exclusion Criteria:

- Participated in clinical trial(s) during the past 36 months.

- Is considering participation in a clinical trial within the next 12 months.

Study Design

Observational Model: Cohort


Related Conditions & MeSH terms


Intervention

Other:
Retrospective Chart Review
Retrospective chart review for up to 36 months of enrollment date.
Patient-reported Outcome Questionnaires
Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
Physician Survey
Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Utilizing Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Therapies for First-line Treatment The number of participants who received ITP therapies for first-line treatment during either the retrospective or prospective phases of the study. Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). No
Primary The Number of Participants Utilizing ITP Therapies for Second-line Treatment. The number of participants who received ITP therapies for second-line treatment during either the retrospective or prospective phases of the study. Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). No
Primary The Number of Participants Utilizing ITP Therapies for Third-line Treatment. The number of participants who received ITP therapies for third-line treatment during either the retrospective or prospective phases of the study. Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). No
Primary The Number of Participants Utilizing ITP Therapies for Fourth-line Treatment. The number of participants who received ITP therapies for fourth-line treatment during either the retrospective or prospective phases of the study. Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). No
Primary The Number of Participants Utilizing ITP Therapies for Fifth-line Treatment The number of participants who received ITP therapies for fifth-line treatment during either the retrospective or prospective phases of the study. Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). No
Primary The Number of Participants Utilizing ITP Therapies for Sixth-line Treatment. Assessed the number of participants who received ITP therapies for sixth-line treatment during either the retrospective or prospective phases of the study. Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). No
Primary The Number of Participants Utilizing ITP Therapies for Seventh or Greater-line Treatment. The number participants who received ITP therapies as seventh or greater-line treatment during either the retrospective or prospective phases of the study. Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). No
Primary The Number of Participants Utilizing ITP Therapies: Treatments With Unknown Starting Date. The number of participants who received ITP therapies for treatments with unknown starting date during either the retrospective or prospective phases of the study. Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). No
Secondary Change From Baseline to Month 12 in Quality of Life Measured by the ITP-Patient Assessment Questionnaire (PAQ) The Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ) was developed to assess disease-specific quality of life (QoL) in adults with ITP. It is a 44-item questionnaire that includes scales for physical health (symptoms, fatigue/sleep, bother, and activity), emotional health (psychological and fear), overall QoL, social activity, women's reproductive health, and work. Scores for each scale range from 0 (worst) to 100 (best). Baseline to month 12 during prospective data collection phase No
Secondary Change From Baseline to Month 12 in Health-related Quality of Life Assessed by EuroQol Visual Analog Scale (EQ-5D VAS) The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' (score = 100) and 'Worst imaginable health state' (score = 0). Baseline to Month 12 during prospective data collection phase No
Secondary Change From Baseline to Month 12 in Treatment Satisfaction Participant satisfaction with treatment was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM), an 11-item questionnaire providing scores on four scales - side effects, effectiveness, convenience and global satisfaction. TSQM Scale scores range from 0 to 100 with higher scores indicating more satisfaction with treatment. Baseline to Month 12 during prospective data collection phase No
Secondary Number of Participants Receiving Drug Therapies for Treatment of ITP During the Prospective Phase The number of participants who received drug therapies for the treatment of ITP during the prospective phase of the study. Use of multiple medications by the same participants is possible. 12 months (prospective data collection phase) No
Secondary Duration of Exposure to ITP Medication Duration of exposure to each ITP medication measured from enrollment until the end of the 12-month data collection phase. 12 months (prospective data collection phase) No
Secondary Number of Participants Requiring Splenectomy The number of participants who required a splenectomy during the 12-month prospective phase of the study. 12 months No
See also
  Status Clinical Trial Phase
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT03633019 - High-dose Use of rhTPO in CIT Patients Phase 4
Recruiting NCT06087198 - Clinical Performance Evaluation of T-TAS®01 HD Chip
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Active, not recruiting NCT03688191 - Study of Sirolimus in CTD-TP in China Phase 4
Completed NCT02845609 - Efficacy of Sialic Acid GNE Related Thrombocytopenia Phase 2
Recruiting NCT02244658 - Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia Phase 3
Recruiting NCT02241031 - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Phase 2/Phase 3
Unknown status NCT01196884 - Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
Completed NCT01356576 - Effect of Hemodialysis Membranes on Platelet Count N/A
Terminated NCT01368211 - Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study) Phase 2/Phase 3
Completed NCT00039858 - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Phase 4
Completed NCT00787241 - Platelet Count Trends in Pre-eclamptic Parturients N/A
Completed NCT00001533 - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine Phase 1
Not yet recruiting NCT06036966 - The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients Phase 2
Completed NCT01791101 - Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia. Phase 2
Recruiting NCT06053021 - Antiplatelet Therapy for AIS Patients With Thrombocytopenia N/A
Recruiting NCT03701217 - Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML Phase 2/Phase 3
Not yet recruiting NCT05958511 - Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients